Lilly's Asset Management Program
Executive Summary
Eli Lilly & Co.'s recent explosion of dealmaking in the seemingly disparate areas of combinatorial chemistry and drug delivery are in fact closely linked by Lilly's approach towards asset management.
You may also be interested in...
Inside Lilly Research Laboratories: A Discussion With Jan Lundberg
Unbowed by a string of recent pipeline setbacks, Lilly Research Labs' new leader speaks out about his company's current trajectory and his belief in ongoing initiatives like Chorus and a mirror fund as Lilly attempts to bridge its patent cliff.
Amarin Investor Heat Intensifies, Despite ‘Unprecedented’ Vascepa Fortitude
The brouhaha between Amarin and its largest shareholder has continued apace, with a smorgasbord of verbal volleys launched against the company, ahead of Amarin’s general meeting of shareholders later this month.
Deals In 2023: Partnerships And Modest M&A
Mid-sized M&A, collaborations, creative financing, and biotech consolidation will feature in 2023. IPOs and follow-ons play bit-parts.